Table 1

Patient demographics, underlying fibrotic lung disease clinical subtype, and background PH-targeted therapy

Patient characteristicsN=15
MeanSD
Age in years6315
NPer cent
NYHA class
 III853
 IV747
Race
 Hispanic853
 Caucasian427
 Filipino/Japanese213
 Middle Eastern17
Fibrotic lung disease clinical subtype
 Idiopathic pulmonary fibrosis853
 NSIP-fibrosis213
 PF/emphysema (CPFE)320
 Chronic Hypersensitivity Pneumonitis (HP)17
 Silicosis17
Background therapy
 Sildenafil monotherapy427
 Bosentan monotherapy213
 Sildenafil/bosentan combination320
 None640
  • CPFE, combined pulmonary fibrosis/emphysema; NSIP, non-specific interstitial pneumonia; NYHA, New York Heart Association; PF, pulmonary fibrosis; PH, pulmonary hypertension.